Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC)

Vito Lorusso, Francesco Carpagnano, Gaetano Di Rienzo, Annamaria Catino, Marco Luigi Cisternino, Michele Guida, Mario Brandi, Agnese Latorre, Salvatore Parisi, Rosa Ricco, Mario De Lena

Research output: Contribution to journalArticlepeer-review


Thirty patients with marginally resectable stage IIIA or stage IIIB NSCLC were treated with cisplatin (80 mg/m2/i.v./dl), ifosfamide (4,000 mg/m2/i.v./dl) and vinorelbine (30 mg/m2/i.v./dl) plus G-CSF 300 μg/s.c. on days 7-12 every 14 days for three cycles before surgery. In 26 evaluable patients, the radiographically assessed response rate to chemotherapy was 77% (8% complete). Three septic deaths (10%) occurred in spite of G-CSF and 1 patient refused to continue after the first cycle. Thoracotomy was performed in 23 patients including 19 complete resections. At 15 months median follow-up (range 10-22+), 11/19 (57%) completely resected patients relapsed. The overall median time to treatment failure was 11 months (range 0-17). Actuarial survival probability at 12, 18 and 24 months are 56%, 43% and 36%, respectively. In conclusion, the combination of cisplatin, ifosfamide and vinorelbine in full doses at a 14 day interval (accelerated chemotherapy) was very effective in neoadjuvant NSCLC setting. Nevertheless, relevant toxicity was demonstrated with a 10% death rate probably due to the overlapping toxicity of chemotherapy cycles, suggesting the need for a more intense supportive care or longer interval between cycles.

Original languageEnglish
Pages (from-to)675-680
Number of pages6
JournalInternational Journal of Oncology
Issue number4
Publication statusPublished - Apr 1996


  • Lung cancer
  • Preoperative chemotherapy
  • Surgery

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this